Small Intestinal Absorption in Patients With Chronic Obstructive Pulmonary Disease and Cor Pulmonale

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

Small Intestinal Absorption in Patients With Chronic Obstructive Pulmonary Disease Complicated by Cor Pulmonale: A Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03243994
• Other study ID #: H-15019987
• Status: Completed
• Phase: N/A
• First received: July 7, 2017
• Last updated: August 4, 2017
• Start date: February 1, 2016
• Est. completion date: October 1, 2016

Study information

• Verified date: August 2017
• Source: University of Copenhagen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Aim: To investigate whether patients with pulmonary hypertension have reduced absorption capacity compared to COPD patients without cor pulmonale potentially due to venous obstruction in the portal vein system.

The presence of cor pulmonale was determined by echocardiography. The concentration of D-xylose and zinc were measured in peripheral blood one, two and three hours after ingestion and used as markers of absorption. Furthermore, urine was collected for five hours to determine the amount of excreted D-xylose.

Description:

Background: Cor pulmonale is a common complication to Chronic Obstructive Pulmonary Disease (COPD), and may result in increased pressure in the inferior caval vein and stasis of the liver. The chronic pulmonary hypertension may lead to stasis in the veins from the small intestine and thereby compromise absorption of nutrients.

Aim: To investigate whether patients with pulmonary hypertension have reduced absorption capacity compared to COPD patients without cor pulmonale.

Methods: Absorption of D-xylose (25 g) and zinc (132 mg), administered as a single dose, was tested in 14 COPD patients, seven with and seven without cor pulmonale. The presence of cor pulmonale was determined by echocardiography. The concentration of D-xylose and zinc were measured in peripheral blood one, two and three hours after ingestion and used as markers of absorption. Furthermore, urine was collected for five hours to determine the amount of excreted D-xylose.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: October 1, 2016
• Est. primary completion date: October 1, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• A diagnosis of COPD

• Clinically stable = Unchanged medication for COPD for at least 6 months

Exclusion Criteria:

• Unable to understand Danish

• Other clinically important heart-disease than chronic right heart changes presumably due to lung disease

• Clinically significant gastro-intestinal or kidney disease

• Diabetes

• Treatment with corticosteroids for at least 6 months.

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Cor Pulmonale
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive
• Pulmonary Heart Disease

Intervention

Diagnostic Test:
• Absorption test with D-xylose and zink
Absorption of D-xylose (25 g) and zinc (132 mg), administered as a single dose. The concentration of D-xylose and zinc was measured in peripheral blood one, two and three hours after ingestion and used as markers of absorption. Furthermore, urine was collected for five hours to determine the amount of excreted D-xylose.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Jens Rikardt Andersen

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Absorption fraction of D-xylose	plasma concentration, mmol/l	3 hours
Secondary	Absorption of zinc	plasma concentration, micromol/l	3 hours
Secondary	Absorption fraction of D-xylose	urine excretion, mmol	5 hours